• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.19% Nasdaq Up0.37%

    Regeneron Pharmaceuticals, Inc. (REGN)

    562.38 Down 5.09(0.90%) 12:47PM EST - Nasdaq Real Time Price
    ProfileGet Profile for:
    Regeneron Pharmaceuticals, Inc.
    777 Old Saw Mill River Road
    Tarrytown, NY 10591
    United States - Map
    Phone: 914-847-7000
    Website: http://www.regeneron.com

    Index Membership:N/A
    Full Time Employees:3,535

    Business Summary 

    Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company’s trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has collaborations with Sanofi and Mitsubishi Tanabe Pharma Corporation; license and collaboration agreement with Bayer HealthCare; and Avalanche Biotechnologies, Inc., as well as Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. The company was founded in 1988 and is headquartered in Tarrytown, New York.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Regeneron Pharmaceuticals, Inc.

    Corporate Governance 
    Regeneron Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 10. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 10; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Leonard S. Schleifer M.D., Ph.D., 62
    Co-Founder, Chief Exec. Officer, Pres, Exec. Director and Ex-Officio Member of Technology Committee
    Dr. Alfred G. Gilman M.D., Ph.D., 73
    Co-Founder, Independent Director, Chairman of Corp. Governance & Compliance Committee and Member of Technology Committee
    Mr. Robert E. Landry Jr., 51
    Chief Financial Officer and Sr. VP of Fin.
    Mr. George D. Yancopoulos M.D., Ph.D., 55
    Chief Scientific Officer, Director, Member of Technology Committee and Pres of Regeneron Research Laboratories
    Dr. Neil Stahl Ph.D., 58
    Exec. VP of R&D
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders